staurosporine has been researched along with n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Flajolet, M; Greengard, P; Meijer, L | 1 |
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Jagarlapudi, SA; Sinha, BN; Tajne, S; Vadivelan, S | 1 |
| Billadeau, DD; Blond, SY; Gaisina, IN; Gallier, F; Guo, S; Holzle, D; Kim, KH; Kozikowski, AP; Kurome, T; Luchini, DN; Ougolkov, AV | 1 |
| Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A | 1 |
| Dou, X; Jiang, L; Jin, H; Liu, Z; Wang, Y; Zhang, L | 1 |
| Bovi, G; Buonfiglio, R; Cavarischia, C; Di Giorgio, FP; di Matteo, A; Furlotti, G; Garrone, B; Mangano, G; Oggianu, L; Olivieri, S; Ombrato, R; Picollo, R; Porceddu, PF; Prati, F; Reggiani, A | 1 |
| Chen, H; Gao, Y; Huang, Y; Jiang, X; Li, D; Liu, W; Liu, X; Wang, N; Wu, L; Xu, Z; Zhao, Q; Zhou, L | 1 |
1 review(s) available for staurosporine and n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea
| Article | Year |
|---|---|
Pharmacological inhibitors of glycogen synthase kinase 3.
Topics: Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Humans; Neoplasms; Nervous System Diseases; Parasitic Diseases; Signal Transduction; Stem Cells; Structure-Activity Relationship | 2004 |
7 other study(ies) available for staurosporine and n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea
| Article | Year |
|---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models.
Topics: Algorithms; Computer Simulation; Databases, Factual; Drug Design; Drug Evaluation, Preclinical; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Models, Chemical; Models, Molecular; Molecular Structure; Oxazines; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Stereoisomerism; Structure-Activity Relationship | 2009 |
From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Benzofurans; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase 2; Drug Screening Assays, Antitumor; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Maleimides; Models, Molecular; Pancreatic Neoplasms; Structure-Activity Relationship; X-Linked Inhibitor of Apoptosis Protein | 2009 |
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase | 2013 |
Discovery of new GSK-3β inhibitors through structure-based virtual screening.
Topics: Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Glycogen Synthase Kinase 3 beta; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship | 2018 |
Optimization of Indazole-Based GSK-3 Inhibitors with Mitigated hERG Issue and
Topics: | 2020 |
Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Antineoplastic Agents; Apoptosis; Carbolines; Cell Line, Tumor; Cell Proliferation; Cholinesterase Inhibitors; Drug Design; Glycogen Synthase Kinase 3 beta; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; Protein Kinase Inhibitors; Signal Transduction; Structure-Activity Relationship | 2022 |